[Management of residual masses of testis germ cell tumors].
Principes de prise en charge des masses résiduelles des tumeurs germinales du testicule.
Masses résiduelles
Residual masses
Testis germinal tumors
Tumeurs germinales du testicule
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
18
07
2018
revised:
27
10
2019
accepted:
30
10
2019
pubmed:
29
12
2019
medline:
7
3
2020
entrez:
29
12
2019
Statut:
ppublish
Résumé
A residual mass (RM) is an abnormal image with a transverse axis of more than 1cm trans that remains visible on the CT scan performed after chemotherapy for metastatic germ cell tumors. Their management depends on the histology of the initial tumor. In the case of a non-seminomatous germ cell tumor, all residual lesions must be resected if the tumor markers are negative. The surgery usually begins with a retroperitoneal lymphadenectomy. This lymphadenectomy is a programed regional surgery and not the only resection of visible masses. All RM must be resected, regardless of their location, and may require successive actions. In order to limit its morbidity, modifications on the extent of the lymphadenectomy and the use of minimally invasive approaches are proposed by some center. When the initial tumor is a pure seminoma the attitude is different: the decay of the masses in post chemotherapy is often postponed. If lesions less than 3cm can be monitored, the others benefit from 18FDG PET at the end of chemotherapy: a positive attachment to PET is suspected of the presence of residual active tissue. The surgery of these RM is curative. If its extent is precise in the case of non-seminomatous tumor, it is more controversial in the case of seminoma. In the case of residual markers, surgery has a place in very specific situations.
Identifiants
pubmed: 31882267
pii: S0007-4551(19)30414-X
doi: 10.1016/j.bulcan.2019.10.010
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
215-223Informations de copyright
Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.